Member Info for crumbs

Splash some cash... please throw some our way next:)

“The agreement will give us access to lipids from Ramot that complement BioNTech’s existing mRNA delivery technologies,” said Prof. Dr. Ugur Sahin, Co-Founder and Chief Executive Officer of BioNTech. “Novel lipid compositions enable us to diversify our application portfolio, especially when there is a need to carry large payloads for genome editing and additions in rare diseases, cancer therapy and many other indications.”

“We are proud to have BioNTech as a licensing partner to further evaluate the use of our novel lipids which we are developing under our Tel Aviv University Technology Innovation Momentum Fund program,” said Shlomo Nimrodi, Chief Executive Officer of Ramot.

Read more: http://www.digitaljournal.com/pr/4073563

Fingers crossed :)

European biotech an attractive option for Chinese investment says VC exec
14-Dec-2018 By Flora Southey

Chinese investors are looking abroad for technology that will provide short-term returns and long-term health benefits to its large patient population, according to Panacea Ventures partner.

HTTPS://WWW.BIOPHARMA-REPORTER.COM/ARTICLE/2018/12/14/CHINESE-COMPANIES-INVESTING-IN-EUROPEAN-BIOTECH

We all know the sp could change completely and forever on one commercial deal is done RNS but it is the one RNS that keeps evading us lol... still much to be positive about here and I noted RG in his last proactive vid at the beginning of the year mentioned commercial talks with companies were ongoing and expect news so... things take time but if anything is coming from those talks it could come anytime now...

I thought the plan was clear? At least since Chippers arrived... Anyways the SCIB1 trial is a must due to the fact it is our most advanced most proven to work product and it has been manufactured already!... shame about the FDA holding things up but surely it is just a process now that will end with approval...
TCR... scancell are not in on TCR we are hoping to license out moditope to improve TCR's effectively at the moment BioNtech are getting to see what cytotoxic CD4 T cells can do!...I think they will be impressed but moditope will be most valuable in its vaccine setting (if it works) ... and that trial is just waiting for the manufacturing issues to be overcome which from AGM seems like will be very soon.. the only part of plan that is troubling and opaque is funding... we want none dilutive funding and BOD working on it but so far funding has come from market ... imagine if they needed funds ASAP.. it would be a 5p raising! aghh luckily we have some time but that will be running out by end of next year.

I'm supposing the thinking behind using Ichor .2 is that it is a commercial device... SCIB1 would be a commercial ready product so much easier for a deal to be done and get it to market then... still very positive about that trial glad there has been put in place a last resort UK insurance arm but I think we will get our US trial and it will be in the hands of the real opinion makers over there which is priceless.... So it could well be that scancell is so confident in trial results that it will not do a lesser deal on anything now when it is confident it can do greater ones on results... not sure that is the case though lol.... anyways having a nice none ip diluting BioNtech I have a feeling that will impress them and note they have not begun their first clinical TCR trial this year yet had one pencilled in....maybe as they are going now to do their first one using moditope? hmm we can hope

Indeed and fact that Amgen has managed to make T-VEC a treatment we have discussed here in past to be a commercial combo product just adds to the bafflement of no immunobody deal/s (ok CRUK one can be seen as a deal but not commercial) as surely it is a lesser tech than SCIB1!!!? but well done to them, not sure if what they will make on it will be as much as what they have invested in it though....

Yes, something that I can't explain and is a worry... Ichor an issue?... of course adds an extra layer of complexity to any potential deal however not a fatal one Ichor has deals with big pharmas and has now produced a commercially ready device (the one we will be using) so Pfizer who helped create that device and want in on cancer vaccines did not want to have a bite at SCIB1 ... hmm... anyways on that front I am happy that scancell have not sat still and now are looking towards nano delivery this is something that makes me positive about scancell they do look to solutions to problems...think Sally Adams is a great asset!... Cancer vaccine unpopular- yes and always previously failed in trials that is not the case with ImmunoBody though is it... it is successfully trialled cancer vaccine-still no deal.....ok CI is where it is at and yes it is shrewd to do a CI combo trial but does smack of done by need, not the necessity as pharma are not interested in ImmunoBody the universal antigen delivery platform as safe early stage disease solution but as a possible CI combo booster...perhaps we have focused too much on the west for action and not to the east but that is not the case now too so that brings some hope with it....as ever though it is a wait and watch (as sp goes down)

I suppose 2018 up to now has turned into an anticlimax year....It was to be the year when scancells tech went into patients once again... but never happened...It will happen though and 2019 looks like the year... funding is going to be our biggest uncertainty historically scancell has always had to raise from market which means this current sp and seeing as we are already well below the last raising price it is not a good situation to be in or very attractive to ii ......as ever we need a commercial deal to change everything!.. how close to one we are I'm not sure BioNtech is looking most likely and listening to AGM it sounded like BOD is working hard on that and not just the lab collaboration part...whar p's me off is the mantra that we need clinical data for deals... well we already have some! Np SCIB1 deal and we see weekly preclinical deals and very good deals at that! ... so why not us? why does scancell have to run at full risk to it's investors it's own trials... yes great to keep IP but it is not the way other successful biotechs do it.... BioNtech being a good example with their multiple partnerships

Turn your Biotech startup into a successful company:

BioNTech AG. Founded in 2008, the company started with a handful of employees, but has grown to employ more than 850 people as Europe’s largest private biotech company working in immunotherapies.

Dr. Ugur Sahin, an accomplished immunologist and experimental cancer researcher, is one of the founders of BioNTech. His research as a professor at the Johannes-Gutenberg University Mainz in the fields of oncology, hematology and immunology, laid the foundation for BioNTech’s success.

Although scientific knowledge and experience are a prerequisite to success, another important aspect is funding: “In order to further pursue research in cancer immunology, to further develop Dr. Sahin’s promising research in the field, and to bring new drug candidates to clinical development, funding was critical,” explains Sean Marett, Chief Business and Commercial Officer at BioNTech.

In January 2018, for instance, the company secured $270 million (€237 million) in a series A financing round. The biotech company will use this capital to work on its clinical pipeline of individualized immunotherapies, which covers novel approaches such as mRNA and CAR-T for the treatment of cancer and other diseases.

And just this August, BioNTech signed a collaboration agreement with Pfizer for the development of prophylactic mRNA-based vaccine candidates against influenza. Together, they will jointly conduct research, and BioNTech is set to receive a total of $425 million (€374 million) in research, R&D and commercial payments in case a product should be brought to market one day.

Marett sees BioNTech’s secret to success in its “broad scientific knowledge base, and a diverse and experienced team, which brings different perspectives together.” Only then, says Marett, can a biotech company become successful.

https://labiotech.eu/sponsored/guide-biotech-startup-successful-company/

Yeah, that is how Genentech roll they like to get in as early as possible -pre clincal... but we are told nah only great clinical data will get you a great deal though great SCIB1 clinical data did not get that product a great deal or any deal infact!...

A re-viewing...as we head towards 2019....RG's last proactive video announcing the BioNtech collaboration... that is looking likely to be our first commercial action- hopefully early 2019 seeing as it is nearly a year in already... interesting he hints in it our collaboration with them on ptoject blueprint too.. and possibly other things hmm....anyways like I say worth an end of year review...
https://www.youtube.com/watch?v=2PFQ9sLXO_8

Seeing as scancell have had to do some more tests for FDA seems so... hopefully all done dusted and waiting for a reply from FDA now

Well done them... though it looks like another AIM bio announced some err 'news' that has given their sp a bigger rise than Avactas nice solid commercial deal news... markets huh maybe that will correct itself through the day or week.

Yeah... Ichor have more to lose than scancell considering we are now looking beyond electroporation... hopefully our trial will get going as early into the first half of 2019 as possible... glad that scancell have added the UK insurance arm to the trial just in case... after all that vaccine has been made already (at great cost) and is just waiting for the green lights to go into patients... but anyways we should heartened by Doc Kims words :

'The patient achieved a complete response, which has sustained for over two years and counting. Increasing evidence suggests that response rates from checkpoint inhibitors can be enhanced when used in combination with cancer vaccines like MEDI0457 that generate tumor-specific T cells'

As we know our cancer vaccine platform is the best way to generate those tumour specific T cells :) ... they have managed commercial deals though which is something we need to see here hopefully soon

To see Inovio have got their CI combo trial running... they managed to get theirs with a deal with Medimmune(Astrazeneca).....anyways wishing them every success as it would be a boost to ImmunoBody's deal potential....

'Dr. J. Joseph Kim, Inovio’s President and Chief Executive Officer, said, “We are pleased to see Inovio’s cancer-fighting immunotherapy, in MEDI0457, expand to new cancer indications. Such expansion is great for patients and the oncology community. For Inovio, amplification of HPV cancer targets holds the potential to bring about additional milestone and royalty payments.”

An article in the online edition of Clinical Cancer Research highlights a recent Phase 1 study of MEDI0457 as a monotherapy in 22 HPV-positive patients with HPV-associated head and neck cancer that demonstrated MEDI0457 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue. One patient in that trial who initially displayed a slight increase in T cell immune responses developed progressive disease at 11 months into the study and subsequently received a PD-1 checkpoint inhibitor. The patient achieved a complete response, which has sustained for over two years and counting. Increasing evidence suggests that response rates from checkpoint inhibitors can be enhanced when used in combination with cancer vaccines like MEDI0457 that generate tumor-specific T cells.'
https://globenewswire.com/news-release/2018/12/04/1661586/0/en/Inovio-Announces-Initiation-of-MD-Anderson-s-HPV-Related-Cancers-Moon-Shot-Phase-2-Trial-in-New-HPV-Indications.html

Now come on Ichor!

Cancer will probably NEVER be eradicated, say Nobel Prize winners who developed the most promising cancer therapy to date.

'Honjo, who will receive the award with Allison in Stockholm on Monday, said he expects that immunotherapy will eventually be used against most cancers, often in combination with radiation or chemotherapy.

He believes that cancer can effectively be stalled 'even if we cannot completely eliminate the tumor, if we can survive with some tumor.'

'I think what is coming next are triple combinations and quadruple combinations,' Allison said.

Although immunotherapy is an advance against cancer treatment, the costs are high, with courses of treatment reportedly exceeding $100,000.

'Something's going to happen' about the cost, Allison said.

'These high prices are not just a feature of these drugs — it's almost everything. ... It's out of control. We've just got to hope that with completion and wisdom the prices will come down.'

https://www.dailymail.co.uk/health/article-6469035/Cancer-NEVER-eradicated-say-Nobel-Prize-winners.html

'Multidisciplinary researchers at the Francis Crick Institute will use state of the art technologies, including deep learning and artificial intelligence tools, to analyse tumour samples and data from TRACERx and PEACE. This will allow them to map an atlas of immune cell activity across distinct tumour regions, and to understand how the incredibly complex tumour immune microenvironment evolves and develops over time.

Veronique Birault, head of translation at the Francis Crick Institute, said: “This project is a fantastic example of the industry and charity sectors working together to support world-class discovery science for the benefit of patients. The project wouldn’t be possible without Cancer Research UK’s significant investment in research, amplified by the complementary expertise of three different cancer labs collaborating at the Crick. This new funding will allow our scientists to map out the immune landscape around lung tumours to develop better combination therapies for patients.”

Dr Iain Foulkes, Cancer Research UK’s executive director of research and innovation, said: “We’re pleased to bring together these partners of industry and academia to advance this ambitious study. As we delve ever deeper into the tumour microenvironment, we can equip ourselves with the necessary knowledge to take the next steps toward truly personalised cancer treatments.

“Lung cancer is a disease for which there has been very little improvement in patient survival over the last 40 years. We look forward to seeing how new treatment combinations that arise from this study could make a real difference for these patients.”

Bristol-Myers Squibb will provide £2.4 million in funding for the RUBICON project.

“Bristol-Myers Squibb is proud to be part of this innovative research initiative. We look for first-class science everywhere and we know that continued progress in cancer can only happen through strong collaboration with scientists, academic researchers, clinicians and patients who participated in clinical trials,” said Tom Lynch, M.D., Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb. '

https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2018-11-30-cancer-research-uk-the-francis-crick-institute-and-bristol-myers-squibb-join-forces-to-map-out-lung

As to how mm can walk a share down and up ... it is easy it is all about controlling the spread baby all about the spread... you can let a share drop on any sell but not let it raise on any buy and vice versa...I also think codes are probably nonsense but the power of selling 100 shares after bigger buys and the sp dropping is algotastic!

The easiest way would be for whoever sold 100 to claim it .... I bought some today and seems more people bought shares than sold shares yet the sp dropped... an interesting algorithm that!

hmm.. what happened to a TCR BioNtech deal?... seems to have been conveniently shelved by certain posters-why?
It will be 12 months in January since scancell began collaborating with BioNtech...we know it has so far gone well...Lindys words those not mine...we know they are not just looking at modi1 but modi2 too...I do not think they will be waiting for 2020 to be doing a commercial deal on moditope... watch this space and with them come Genentech who are very closely working with them on personalised vaccines and what is project blueprint all about oh personalised vaccines for all led by one Lindy Durrant with Ira Mellman of Genentech/Roche working under her as a team member looking at utilising a modi3 (basically moditope combos utilising BioNtech and Genentech's very costly techs)....of course the focus here is on trial data.. and yes scancell failed to turn SCIB1 trial data into a commercial deal but they have not stopped working on it..... I think the move away from electroporation and Ichor fits in with that..so by 2020 yes should be data in but commercial action could be coming anytime.... glyca MABs up for deals too don't forget.